These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9462444)

  • 1. Effects of in-vitro activity of miconazole and ketoconazole in phospholipid formulations.
    De Logu A; Fadda AM; Anchisi C; Maccioni AM; Sinico C; Schivo ML; Alhaique F
    J Antimicrob Chemother; 1997 Dec; 40(6):889-93. PubMed ID: 9462444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention by L-alpha-phosphatidylcholine of antifungal activity in vitro of liposome-encapsulated imidazoles determined by using time-killing curves.
    De Logu A; Fadda AM; Pellerano ML; Diana G; Schivo ML
    Int J Antimicrob Agents; 2000 Jun; 15(1):43-8. PubMed ID: 10856676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness, in vitro, of miconazole and ketoconazole combined with tissue conditioners in inhibiting the growth of Candida albicans.
    Quinn DM
    J Oral Rehabil; 1985 Mar; 12(2):177-82. PubMed ID: 3886866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative study of two systems for the determination of the sensitivity of yeasts to antifungal agents].
    de Montclos M; de Montclos H; Flandrois JP
    Pathol Biol (Paris); 1992 May; 40(5):495-9. PubMed ID: 1495833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of miconazole, ketoconazole and fluconazole in their effects on temperature-dependent growth and thermal death in Candida albicans.
    Madeira-Lopes A; Miranda J
    J Med Vet Mycol; 1995; 33(6):375-8. PubMed ID: 8683405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A replica plating technique for in vitro study of susceptibility of Candida albicans to miconazole, econazole and ketoconazole: some data for standardization.
    Sanchez-Sousa A; Gomez-Criado C; Jimenez ML; Fernandez-Jorge A; Baquero F
    Ann Inst Pasteur Microbiol (1985); 1985; 136A(3):371-80. PubMed ID: 3901880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth phase in relation to ketoconazole and miconazole susceptibilities of Candida albicans.
    Beggs WH
    Antimicrob Agents Chemother; 1984 Mar; 25(3):316-8. PubMed ID: 6326664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azole sensitivity in Candida albicans.
    Armelles M
    FEMS Microbiol Lett; 1989 Jul; 51(1):153-7. PubMed ID: 2673916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irrelevance of growth phase with respect to the Bay n 7133 and ICI 153,066 susceptibilities of Candida albicans.
    Beggs WH; Hughes CE
    Diagn Microbiol Infect Dis; 1986 Jan; 4(1):83-6. PubMed ID: 3510807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative action of 8 azole derivatives against Candida albicans: fungistatic action and cytologic study by scanning electron microscopy].
    Mallie M; Jouvert S; Bastide M; Montes B; Lebecq JC; Bastide JM
    Pathol Biol (Paris); 1988 May; 36(5):575-80. PubMed ID: 3043361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of a new derivative: N-(4-chlorobenzyl)-2-(1H-imidazol-1-ylmethyl)benzenamine.
    Panico S; Villa A; Simonetti N; Porretta GC; Scalzo M
    Drugs Exp Clin Res; 1990; 16(4):181-6. PubMed ID: 2076654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of antifungal drugs on adherence of Candida albicans to buccal epithelial cells.
    Brenciaglia MI; Ghezzi MC; Cipriani P; Mancini C; Trancassini M
    Chemioterapia; 1986 Jun; 5(3):200-3. PubMed ID: 3521918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo pharmacokinetics and pharmacodynamics of topical ketoconazole and miconazole in human stratum corneum.
    Pershing LK; Corlett J; Jorgensen C
    Antimicrob Agents Chemother; 1994 Jan; 38(1):90-5. PubMed ID: 8141586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of antimicrobial agents incorporated into resilient denture relines on the Candida albicans biofilm.
    Bueno MG; Urban VM; Barbério GS; da Silva WJ; Porto VC; Pinto L; Neppelenbroek KH
    Oral Dis; 2015 Jan; 21(1):57-65. PubMed ID: 24219354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of imidazole antifungals on the development of germ tubes by strains of Candida albicans.
    Johnson EM; Richardson MD; Warnock DW
    J Antimicrob Chemother; 1983 Oct; 12(4):303-16. PubMed ID: 6315670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of using collagen as the base of the antifungal drug, miconazole.
    Yoshida K; Hirai K; Ara T; Ito M; Wang PL; Igarashi Y
    J Oral Rehabil; 2006 May; 33(5):363-7. PubMed ID: 16629895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fungicidal activity of tioconazole in relation to growth phase of Candida albicans and Candida parapsilosis.
    Beggs WH
    Antimicrob Agents Chemother; 1984 Nov; 26(5):699-701. PubMed ID: 6097174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro effect of itraconazole against various species of Candida].
    Bastide M; Mallie M; Jouvert S; Montes B; Bastide JM
    Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):694-9. PubMed ID: 2552381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility studies with oxiconazole (Ro 13-8996).
    Gebhart RJ; Espinel-Ingroff A; Shadomy S
    Chemotherapy; 1984; 30(4):244-7. PubMed ID: 6086246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The comparison of susceptibility of Candida albicans and Candida glabrata to miconazole].
    Kurnatowski P; Makieło L; Horwatt-Bozyczko E
    Wiad Parazytol; 2001; 47(4):867-73. PubMed ID: 16886440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.